Current Report


 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

Form 8-K

 

 

CURRENT REPORT

 

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): August 14, 2002

 

 

 

Bio-Technology General Corp.

(Exact name of issuer as specified in its charter)

 

 

Delaware

 

0-15313

 

13-3033811

 

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

 

 

 

 

 

 

70 Wood Avenue South

 

 

 

Iselin, New Jersey

 

08830

 

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

(732) 632-8800

(Registrant’s telephone number, including area code)

 

 

None.

(Former address, if changed since last report.)

 

 

 



 

 

ITEM 7.      FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

                                                (a)           Financial Statements of Business Acquired.

 

                                                                None.

 

                                                (b)           Pro Forma Financial Information.

 

                                                                None.

 

                                                (c)           Exhibits.

 

99.1

Certification by Sim Fass pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 in connection with Bio-Technology General Corp.’s Quarterly Report on Form 10-Q for the quarter ended June 20, 2002.

 

 

99.2

Certification by John A. Bond pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 in connection with Bio-Technology General Corp.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002.

 

 

99.3

Certification by Yehuda Sternlicht pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 in connection with Bio-Technology General Corp.’s Quarterly Report on Form 10-Q for the quarter ended June 20, 2002.

 

 

 

ITEM 9.  REGULATION FD DISCLOSURE.

 

                Attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated by reference herein, are the Certifications by Sim Fass, Chief Executive Officer of Bio-Technology General Corp. (the “Company”), John A. Bond, Senior Vice President–Finance and Treasurer of the Company and Yehuda Sternlicht, Vice President–Chief Financial Officer of the Company, respectively, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 in connection with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002 which have personally been signed and delivered to the Securities and Exchange Commission.

 

2



 

SIGNATURES

 

 

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

BIO-TECHNOLOGY GENERAL CORP.

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

By:

/s/ John A. Bond

 

 

 

 

 

John A. Bond

 

 

 

 

 

Senior Vice President-Finance and Treasurer

 

 

Dated: August 14,  2002

 

 

 

3



 

Exhibit 99.1

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Quarterly Report of Bio-Technology General Corp. (the “Company”) on Form 10-Q for the period ended June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sim Fass, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)           The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

 

By:

/s/ Sim Fass

 

 

Sim Fass

 

 

Chief Executive Officer

 

 

August 13, 2002

 

 



Exhibit 99.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Bio-Technology General Corp. (the “Company”) on Form 10-Q for the period ended June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John A. Bond, Senior Vice President - Finance and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)           The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

By:

/s/ John A. Bond

 

 

John A. Bond
Senior Vice President - Finance and Treasurer
August 13, 2002

 



 

Exhibit 99.3

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Quarterly Report of Bio-Technology General Corp. (the “Company”) on Form 10-Q for the period ended June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yehuda Sternlicht, Vice President - Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)           The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

 

By:

/s/ Yehuda Sternlicht

 

 

Yehuda Sternlicht

 

 

Vice President - Chief Financial Officer

 

 

August 13, 2002